THE CELENTYX LEADERSHIP TEAM

Prof. Nicholas Barnes

PRINCIPAL FOUNDER, DIRECTOR & CEO

Nicholas is a Fellow of the British Pharmacological Society, an Honorary Professor at numerous universities around the globe and is one of the World's most highly cited researchers (Clarivate Web of Science Highly Cited Researcher; https://publons.com/researcher/4043005/nicholas-barnes/).
Nicholas has gained an international reputation for his applied research in neuropharmacology and brings to Celentyx his proven track record in the investigation of potential drug targets and the delivery of candidate therapeutics.    ​

PUBLICATIONS

Prof. John Gordon

CO-FOUNDER, DIRECTOR, VP SCIENTIFIC AFFAIRS & CHAIR OF THE ADVISORY PANEL

John  is an internationally recognised authority on immune cell biology and immune cell-mediated diseases. He is one of the World’s most highly cited researchers (www.ISIHighlyCited.com) and has a proven track record in the successful application of research within the field of translational medicine.  

PUBLICATIONS

Dr Catherine Brady

COO

Catherine is the Chief Operating Officer of Celentyx. Formerly Catherine was Innovation Manager for MidTECH – NHS Innovations, a role that identified and managed intellectual property on behalf of the UK National Health Service. Catherine completed a PhD in pharmacology funded by BASF Pharma.

PUBLICATIONS

Dr Omar Qureshi

CSO

Omar is the Chief Scientific Officer of Celentyx. Formerly, Omar was a Senior Scientist at UCB Pharma where he introduced early projects, established high-content imaging technologies, led biomarker subteams and performed mechanistic studies at several stages of the drug discovery process.  Prior to this, his academic work focussed on understanding immune checkpoints.

PUBLICATIONS

---

Prof. John Curnow

CDO

John is the Chief Development Officer of Celentyx and a former Senior Lecturer in the MRC Centre for Immune Regulation at the University of Birmingham. He has a longstanding interest in immunological tolerance and autoimmunity and is a leading expert on human T cells in health and disease with particular interest in CD4+ T helper subsets including Tregs, Th17 and Th22 cells.

PUBLICATIONS

Dr Sam Butterworth

PRINICIPAL SCIENTIST

Sam is a Principal Scientist within Celentyx Ltd and also a Lecturer in Medicinal Chemistry at the University of Manchester. He specialises in the discovery and development of novel anti-cancer therapies and brings a wealth of knowledge to Celentyx Ltd in this area. Sam worked previously in oncology research at AstraZeneca (Alderley Park, UK) and is the lead inventor of mereletinib (also known as osimertinib; marketed under the trade name Tagrisso).

PUBLICATIONS

Prof. Alan Boyd

NON-EXECUTIVE DIRECTOR

Alan brings over 30 years of experience to Celentyx Ltd. A medic by training and a Fellow of the Royal College of Physicians, he is also Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at the Faculty of Pharmaceutical Medicine, Royal College of Physicians. Alan has held senior positions in major pharma companies including Head of Medical Research at Zeneca Pharmaceuticals

Dr Kristian Brock

PRINICIPAL BIOSTATISTICIAN

Kristian is a Principal Biostatistician with extensive experience inputting statistical expertise in multiple pre-clinical and clinical projects including for the Cancer Research UK Clinical Trials Unit. He has a PhD in efficient methods for clinical trials with restricted sample size. Prior to training as a statistician, Kristian worked for nine years as a quantitative equity analyst for the fund manager Schroders

---